Cargando…
Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd and International Society of Antimicrobial Chemotherapy.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833570/ https://www.ncbi.nlm.nih.gov/pubmed/33408022 http://dx.doi.org/10.1016/j.ijantimicag.2020.106176 |
| _version_ | 1783642094568472576 |
|---|---|
| author | dos Santos, Marcelo Rodrigues |
| author_facet | dos Santos, Marcelo Rodrigues |
| author_sort | dos Santos, Marcelo Rodrigues |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7833570 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Ltd and International Society of Antimicrobial Chemotherapy. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78335702021-01-26 Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial dos Santos, Marcelo Rodrigues Int J Antimicrob Agents Letter to the Editor Elsevier Ltd and International Society of Antimicrobial Chemotherapy. 2021-01 2021-01-04 /pmc/articles/PMC7833570/ /pubmed/33408022 http://dx.doi.org/10.1016/j.ijantimicag.2020.106176 Text en © 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor dos Santos, Marcelo Rodrigues Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial |
| title | Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial |
| title_full | Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial |
| title_fullStr | Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial |
| title_full_unstemmed | Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial |
| title_short | Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial |
| title_sort | referring to the study: hydroxychloroquine and azithromycin as a treatment of covid-19: results of an open label non-randomized clinical trial |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833570/ https://www.ncbi.nlm.nih.gov/pubmed/33408022 http://dx.doi.org/10.1016/j.ijantimicag.2020.106176 |
| work_keys_str_mv | AT dossantosmarcelorodrigues referringtothestudyhydroxychloroquineandazithromycinasatreatmentofcovid19resultsofanopenlabelnonrandomizedclinicaltrial |